多发性脑转移患者全脑同期推量调强放疗疗效分析

目的：研究全脑同期推量调强放疗（SimuLtaneous modulated radiotherapy，SMR）对脑多发性转移癌（MuLtiplecerebralmetastaticcarcinoma，MCMC）患者疗效及预后情况。方法：选取我院2010年7月至2013年7月，收治的80例MCMC病患作为观察对象。以数字法随机分成两组。观察组实施全脑SMR，对照组实施常规全脑放疗。对比两组疗效以及预后情况。结果：观察组RR为72．50％（29／40），较对照组的47．50％（19／40）明显高。差异均具有统计学意义（均P〈0．05）。两组病患全部顺利完成治疗，未见Ⅲ级以上NS反应以及2度以上骨髓抑制。观察组恶心、呕吐为0．93±0．15，白细胞降低为1.32±0．21，血小板下降为0．76±0．11，贫血为1．32±0．24，较对照组的1．01±0．12，1．44±0．22，0．82±0．12，1．44±0．25明显更低。结论：全脑SMR治疗MCMC，疗效显著。毒副反应患者可耐受，安全可行，值得推荐。

Curative Effect and Prognosis of whole Brain Simultaneous Modulated Radiotherapy for Patients with Multiple Cerebral Metastatic Carcinoma

Objective： To study the curative effect and prognosis of whole brain simultaneous modulated radiotherapy （SMR ） for multiple cerebral metastatic carcinoma （ MCMC ） patients. Method： The total of 80 MCMC patients in our hospital from July 2010 to July 2013 were randomly divided into two groups. The observation group received whole brain SMR; the control group received routine whole brain radiotherapy, compared the curative effect and prognosis of two groups. Result： The total effective rate in observation group [ 72.50% {29/40} ] was higher than the control group [47.50% { 19/40） ]. The differences were statistically significant （ P〈0.05 ）. Patients of two groups all successfully completed treatment had no neurotoxic reactions above grade III and 2 degrees of bone marrow suppression. The observation group ＇ s nausea, vomiting [0.93 ± 0.15], decreased white blood cells [1.32 ± 0.21], thrornbocytopenia [0.76 ± 0.11] , anemia [1. 32 ±0.24], were lower than the control group＇s [1.01 ± 0.12, 1.44 ± 0.22, 0.82 ± 0.12, 1.44 ±0.25]. The differences were statistically significant （P〈0.05）. Conclusion： Whole brain SMR desirable has a good effect on MCMC patients, Toxicity is acceptable. It is worthy of recommendation.